Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8006-8014

  Willipinski Stapelfeldt, Birthe ^a   Riethdorf, Sabine ^a   Assmann, Volker ^a   Woelfle, Ute ^a   Rau, Thomas ^a   Sauter, Guido ^a   Heukeshoven, Jochen ^b   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BETA TUBULIN; CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; CYTOSKELETON PROTEIN; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 60; PROGESTERONE RECEPTOR; VIMENTIN;

AGE DISTRIBUTION; AMINO ACID SEQUENCE; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GRADING; CANCER SURVIVAL; CELL IMMORTALIZATION; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MESENCHYME CELL; METASTASIS; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; TISSUE MICROARRAY; TUMOR VOLUME; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; KERATINS; MESODERM; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; VIMENTIN;

EID: 28144440871     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0632     Document Type: Article

References (40)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
3. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342: 525-33.
4. Janni W, Hepp F, Rjosk D, et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 2001;92:46-53.
5. Heiss MM, Allgayer H, Gruetzner KU, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995;1: 1035-9.
6. Pantel K, Dickmanns A, Zippelius A, et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 1995;87:1162-8.
7. Putz E, Witter K, Offner S, et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999;59:241-8.
8. Kraus J, Pantel K, Pinkel D, Albertson DG, Speicher MR. High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer 2003;36:159-66.
9. Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer. J Cell Sci 1998;111:1685-94.
10. Görg A, Postel W, Gunther S. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 1988;9:531-46.
11. Görg A, Postel W, Baumer M, Weiss W. Two-dimensional polyacrylamide gel electrophoresis, with immobilized pH gradients in the first dimension, of barley seed proteins: discrimination of cultivars with different malting grades. Electrophoresis 1992;13:192-203.
12. Heukeshoven J, Dernick R. Simplified method for silver staining of proteins in polyacrylamide gels and the mechanism of silver staining. Electrophoresis 1985;6: 103-12.
13. Rohaly G, Chemnitz J, Dehde S, et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005;122:21-32.
14. Simon R, Sauter G, Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 2002;30:1365-672.
15. Woelfle U, Sauter G, Santjer S, Braakenhoff RH, Pantel K. Downregulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 2004;10:2670-4.
16. Nocito A, Bubendorf L, Maria Tinner E, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-57.
17. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56.
18. Bartek J, Bartekova J, Kyprianou N, et al. Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. Proc Natl Acad Sci U S A 1991;88:3520-4.
19. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
20. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203: 661-71.
21. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998;433:119-29.
22. Vincent-Salomon A, Thiery JP. Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003;5:101-6.
23. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2: 442-54.
24. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003;63: 5679-84.
25. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999;91:1113-24.
26. Coulombe PA, Omary MB. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 2002;14: 110-22.
27. Baribault H, Price J, Miyai K, Oshima RG. Mid-gestational lethality in mice lacking keratin 8. Genes Dev 1993;7:1191-202.
28. Toivola DM, Nieminen MI, Hesse M, et al. Disturbances in hepatic cell-cycle regulation in mice with assembly-deficient keratins 8/18. Hepatology 2001;34: 1174-83.
29. Zajchowski DA, Bartholdi MF, Gong Y, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61:5168-78.
30. Hendrix MJ, Seftor A, Seftor RE, Trevor KT. Experimental coexpression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997;150: 483-95.
31. Nielsen T, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
32. Korsching EP, Agelopoulos J, Eisenacher K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82: 1525-33.
33. Weber-Mangal S, Sinn HP, Popp S, et al. Breast cancer in young women (<35 years):genomic aberrations detected by comparative genomic hybridization. Int J Cancer 2003;107:583-92.
34. Chung M CHR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older woman. Cancer 1996;77:97-103.
35. Weidner N, Cady B, Goodson WH III. Pathologic prognostic factors for patients with breast carcinoma. Which factors are important. Surg Oncol Clin N Am 1997;6:415-62.
36. Ellis P, Smith J, Ashley S, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998;16:107-14.
37. Domagala W, Lasota J, Dukowicz A, et al. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol 1990;137:1299-304.
38. Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B, Osborn M. p53 protein and vimentin in invasive ductal NOS breast carcinoma-relationship with survival and sites of metastases. Eur J Cancer 1994;30A:1527-34.
39. Domagala W, Markiewski M, Harezga B, Dukowicz H A, Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res 1996;2:147-54.
40. Heatley MK, Ewings P, Odling Smee W, Maxwell P, Toner PG. Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast. Pathology 2002;34:230-2.